Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Columbia University Medical Center, New York, NY, United States

Survival: 16.9 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Columbia University Medical Center
Journal: Link
Date: 5/2014

This phase 2 study involved 58 mantle cell lymphoma patients who were previously treated with bortezomib. The median patient age was 68 years years and 77.6% were male.

Patients were treated with the biologic therapy agent everolimus, an inhibitor of the mTOR protein that causes cancer cell death.

The most severe toxicities were of grade 4 and included neutropenia, thrombocytopenia, and abdominal pain. Grade 3 fatigue and pneumonia were also reported.

The median overall survival was 16.9 months.

This study was supported by Novartis Pharmaceuticals.

Correspondence: Dr. Owen A. O’Connor; email:

E-mail to a Friend Email Physician More Information